Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

08.11.2026

Xtandi Patent Dispute Heads to Constitutional Court

The Xtandi patent dispute reaches South Africa’s Constitutional Court on 23 November. Read what is at stake for generic access and damages claims.
Xtandi patent dispute over generic prostate cancer medicine Enzutrix in South Africa
Image Supplied

The Xtandi patent dispute will reach South Africa’s Constitutional Court on 23 November 2026, with generic competition and infringement damages at stake.

The court has scheduled applications by Eurolab and Dis-Chem Oncology and related companies against the University of California (UC) and others. The litigation concerns Enzutrix, a generic version of Astellas’s prostate cancer medicine Xtandi.

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

More from Health Matters

06.11.2026

Pharmaceutical Sovereignty Put to the Test by Ebola

Pharmaceutical sovereignty is back in focus as Ebola spreads in the DRC. See how pooled procurement and shared regulation could secure supplies.

05.11.2026

Rare Disease Funding in Focus After KeyHealth Ruling

Rare disease funding is under scrutiny after the KeyHealth ruling. See how schemes could share the cost of treatments such as Ultomiris.

05.11.2026

Essential Medicine Shortages Hit Public Hospitals

Essential medicine shortages threaten 165 public sector products in South Africa. See what is disrupting supply and how the department is responding.